David Z.I Cherney
University Health Network, Toronto General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Z.I Cherney as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07902726 · Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 DiabetesUniversity Health Network, Toronto · not yet recruiting · T2D · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:26 UTC. The ranking covers the 200 most relevant of 89 PubMed records, and a shared surname and initials can bring in a namesake. All 89 on PubMed
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.N Engl J Med · 20201,184 citationsRCR 61.7
- Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.Circulation · 20141,086 citationsRCR 36.9
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.N Engl J Med · 2021957 citationsRCR 62.0
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.Cardiovasc Diabetol · 2014413 citationsRCR 13.7
- 301 citationsRCR 17.3
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.Diabetes Care · 2018290 citationsRCR 11.4
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.Lancet Diabetes Endocrinol · 2022263 citationsRCR 20.9
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.Lancet Diabetes Endocrinol · 2020235 citationsRCR 12.4
- Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.Diabetes Obes Metab · 2018226 citationsRCR 9.6
- Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.Diabetes Care · 2014197 citationsRCR 6.6